## JesÃ<sup>o</sup>s Pintor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6793880/publications.pdf Version: 2024-02-01



ΙεςΔος Ριντορ

#	Article	IF	CITATIONS
1	Presence of diadenosine polyphosphates— Ap4A and Ap5A— In rat brain synaptic terminals. Ca2+ dependent release evoked by 4-aminopyridine and veratridine. Neuroscience Letters, 1992, 136, 141-144.	2.1	143
2	Full sensitivity of P <sub>2times2</sub> purinoceptor to ATP revealed by changing extracellular pH. British Journal of Pharmacology, 1996, 117, 1371-1373.	5.4	127
3	Purines in the eye: Recent evidence for the physiological and pathological role of purines in the RPE, retinal neurons, astrocytes, Müller cells, lens, trabecular meshwork, cornea and lacrimal gland. Experimental Eye Research, 2014, 127, 270-279.	2.6	111
4	Involvement of melatonin MT3 receptors in the regulation of intraocular pressure in rabbits. European Journal of Pharmacology, 2001, 416, 251-254.	3.5	109
5	Characterization and quantification of diadenosine hexaphosphate in chromaffin cells: Granular storage and secretagogue-induced release. Analytical Biochemistry, 1992, 200, 296-300.	2.4	101
6	Melatonin receptors in the eye: Location, second messengers and role in ocular physiology. , 2007, 113, 507-522.		97
7	Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. British Journal of Pharmacology, 2003, 138, 831-836.	5.4	95
8	Tear Secretion Induced by Selective Stimulation of Corneal and Conjunctival Sensory Nerve Fibers. , 2004, 45, 2333.		91
9	A novel receptor for diadenosine polyphosphates coupled to calcium increase in rat midbrain synaptosomes. British Journal of Pharmacology, 1995, 115, 895-902.	5.4	87
10	Diadenosine polyphosphate receptors. , 2000, 87, 103-115.		83
11	Carbachol induced release of diadenosine polyphosphates -Ap4A and Ap5A- from perfused bovine adrenal medulla and isolated chromaffin cells. Life Sciences, 1991, 48, 2317-2324.	4.3	79
12	Ocular Manifestations of Alzheimer's and Other Neurodegenerative Diseases: The Prospect of the Eye as a Tool for the Early Diagnosis of Alzheimer's Disease. Journal of Ophthalmology, 2018, 2018, 1-12.	1.3	69
13	P2 purinergic receptors for diadenosine polyphosphates in the nervous system. General Pharmacology, 1995, 26, 229-235.	0.7	66
14	Selectivity and activity of adenine dinucleotides at recombinant P2x <sub>2</sub> and P2Y <sub>1</sub> purinoceptors. British Journal of Pharmacology, 1996, 119, 1006-1012.	5.4	64
15	Assessment of inner retina dysfunction and progressive ganglion cell loss in a mouse model of glaucoma. Experimental Eye Research, 2014, 122, 40-49.	2.6	64
16	Presence of Diadenosine Polyphosphates in the Aqueous Humor: Their Effect on Intraocular Pressure. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 342-348.	2.5	62
17	Presence of diadenosine polyphosphates in human tears. Pflugers Archiv European Journal of Physiology, 2002, 443, 432-436.	2.8	56
18	The role and therapeutic potential of melatonin in ageâ€related ocular diseases. Journal of Pineal Research, 2017, 63, e12430.	7.4	54

Jesús Pintor

#	Article	IF	CITATIONS
19	The activation of P <sub>1</sub> ―and P <sub>2</sub> â€purinoceptors in the guineaâ€pig left atrium by diadenosine polyphosphates. British Journal of Pharmacology, 1996, 118, 1294-1300.	5.4	50
20	UTP and diadenosine tetraphosphate accelerate wound healing in the rabbit cornea. Ophthalmic and Physiological Optics, 2004, 24, 186-193.	2.0	49
21	Dopamine Receptor Blockade Inhibits the Amphetamineâ€Induced Release of Diadenosine Polyphosphates, Diadenosine Tetraphosphate and Diadenosine Pentaphosphate, from Neostriatum of the Conscious Rat. Journal of Neurochemistry, 1995, 64, 670-676.	3.9	46
22	Immunolocalisation of P2Y receptors in the rat eye. Purinergic Signalling, 2004, 1, 83-90.	2.2	45
23	Signs and Symptoms of Dry Eye in Keratoconus Patients: A Pilot Study. Current Eye Research, 2015, 40, 1088-1094.	1.5	43
24	Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 293-299.	2.5	42
25	Chapter 32 Diadenosine polyphosphates, extracellular function and catabolism. Progress in Brain Research, 1999, 120, 397-409.	1.4	41
26	Effects of Dinucleoside Polyphosphates on Trabecular Meshwork Cells and Aqueous Humor Outflow Facility. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 1042-1051.	2.5	41
27	Increased Levels of Diadenosine Polyphosphates in Dry Eye. , 2006, 47, 4053.		40
28	Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions. European Journal of Pharmacology, 2013, 701, 213-217.	3.5	40
29	Nucleotides in ocular secretions: Their role in ocular physiology. , 2008, 119, 55-73.		39
30	Postâ€lens tear turbidity and visual quality after scleral lens wear. Australasian journal of optometry, The, 2017, 100, 577-582.	1.3	39
31	Dinucleoside polyphosphates in the eye: from physiology to therapeutics. Progress in Retinal and Eye Research, 2007, 26, 674-687.	15.5	37
32	Melatonin Receptors Trigger cAMP Production and Inhibit Chloride Movements in Nonpigmented Ciliary Epithelial Cells. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 119-128.	2.5	36
33	Nucleotides in the Eye: Focus on Functional Aspects and Therapeutic Perspectives. Journal of Pharmacology and Experimental Therapeutics, 2013, 345, 331-341.	2.5	35
34	Amphetamine-induced release of diadenosine polyphosphates - Ap4A and Ap5A - from caudate putamen of conscious rat. Neuroscience Letters, 1993, 150, 13-16.	2.1	33
35	Sympathetic nervous system modulates the ocular hypotensive action of MT <sub>2</sub> â€melatonin receptors in normotensive rabbits. Journal of Pineal Research, 2008, 45, 468-475.	7.4	33
36	Presence of melanopsin in human crystalline lens epithelial cells and its role in melatonin synthesis. Experimental Eye Research, 2017, 154, 168-176.	2.6	33

#	Article	IF	CITATIONS
37	Dry Eye Treatment Based on Contact Lens Drug Delivery: A Review. Eye and Contact Lens, 2016, 42, 280-288.	1.6	31
38	Melatonin and the control of intraocular pressure. Progress in Retinal and Eye Research, 2020, 75, 100798.	15.5	31
39	Corneal Re-epithelialization Stimulated by Diadenosine Polyphosphates Recruits RhoA/ROCK and ERK1/2 Pathways. , 2008, 49, 4982.		30
40	Silencing of P2Y <sub>2</sub> receptors reduces intraocular pressure in New Zealand rabbits. British Journal of Pharmacology, 2012, 165, 1163-1172.	5.4	30
41	Design of Novel Melatonin Analogs for the Reduction of Intraocular Pressure in Normotensive Rabbits. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 703-709.	2.5	29
42	Hyperosmotic stress induces ATP release and changes in P2X7 receptor levels in human corneal and conjunctival epithelial cells. Purinergic Signalling, 2017, 13, 249-258.	2.2	29
43	Hypotensive effect of UDP on intraocular pressure in rabbits. European Journal of Pharmacology, 2008, 579, 93-97.	3.5	28
44	5â€MCAâ€NAT does not act through NQO2 to reduce intraocular pressure in Newâ€Zealand white rabbit. Journal of Pineal Research, 2009, 47, 201-209.	7.4	28
45	Melatonin and Its Analog 5-Methoxycarbonylamino- <i>N</i> -Acetyltryptamine Potentiate Adrenergic Receptor-Mediated Ocular Hypotensive Effects in Rabbits: Significance for Combination Therapy in Glaucoma. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 138-145.	2.5	27
46	Sources of Extracellular Tau and its Signaling. Journal of Alzheimer's Disease, 2014, 40, S7-S15.	2.6	27
47	Increased levels of extracellular ATP in glaucomatous retinas: Possible role of the vesicular nucleotide transporter during the development of the pathology. Molecular Vision, 2015, 21, 1060-70.	1.1	27
48	Dual Roles of Diadenosine Polyphosphates in Corneal Epithelial Cell Migration. , 2006, 47, 4500.		26
49	Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT. Experimental Eye Research, 2009, 88, 504-511.	2.6	26
50	Adenosine Tetraphosphate, Ap4, a Physiological Regulator of Intraocular Pressure in Normotensive Rabbit Eyes. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 468-473.	2.5	25
51	Diadenosine Polyphosphates in Tears of Sjögren Syndrome Patients. , 2010, 51, 5452.		25
52	Glaucoma patients present increased levels of diadenosine tetraphosphate, Ap4A, in the aqueous humour. Experimental Eye Research, 2011, 92, 221-226.	2.6	25
53	Effect of Melatonin and Analogues on Corneal Wound Healing: Involvement of Mt <sub>2</sub> Melatonin Receptor. Current Eye Research, 2015, 40, 56-65.	1.5	25
54	Potential role of P2X7 receptor in neurodegenerative processes in a murine model of glaucoma. Brain Research Bulletin, 2019, 150, 61-74.	3.0	25

#	Article	IF	CITATIONS
55	New treatments for ocular hypertension. Autonomic Neuroscience: Basic and Clinical, 2009, 147, 14-19.	2.8	24
56	TRPV4 activation triggers the release of melatonin from human non-pigmented ciliary epithelial cells. Experimental Eye Research, 2015, 136, 34-37.	2.6	23
57	Adenosine 5′-tetraphosphate (Ap4), a new agonist on rat midbrain synaptic terminal P2 receptors. Neuropharmacology, 2000, 39, 2381-2390.	4.1	22
58	Purinergic Receptors in Ocular Inflammation. Mediators of Inflammation, 2014, 2014, 1-11.	3.0	22
59	The Use of Mucoadhesive Polymers to Enhance the Hypotensive Effect of a Melatonin Analogue, 5-MCA-NAT, in Rabbit Eyes. , 2011, 52, 1507.		21
60	Presence of melatonin in human tears. Journal of Optometry, 2017, 10, 3-4.	1.3	21
61	Docking studies for melatonin receptors. Expert Opinion on Drug Discovery, 2018, 13, 241-248.	5.0	21
62	Diquafosol Delivery from Silicone Hydrogel Contact Lenses: Improved Effect on Tear Secretion. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 170-176.	1.4	21
63	Requirement of intact sympathetic transmission for the ocular hypotensive effects of melatonin and 5-MCA-NAT. Autonomic Neuroscience: Basic and Clinical, 2007, 137, 63-66.	2.8	20
64	Changes in Diadenosine Polyphosphates during Alignment-Fit and Orthokeratology Rigid Gas Permeable Lens Wear. , 2012, 53, 4426.		20
65	In vitro and in vivo delivery of the secretagogue diadenosine tetraphosphate from conventional and silicone hydrogel soft contact lenses. Journal of Optometry, 2013, 6, 205-211.	1.3	20
66	An update on dry eye disease molecular treatment: advances in drug pipelines. Expert Opinion on Pharmacotherapy, 2014, 15, 1371-1390.	1.8	20
67	Therapeutic potential of nucleotides in the eye. Drug Development Research, 2001, 52, 190-195.	2.9	19
68	Nucleotides and dinucleotides in ocular physiology: New possibilities of nucleotides as therapeutic agents in the eye. Drug Development Research, 2003, 59, 136-145.	2.9	19
69	Diadenosine polyphosphates in the central nervous system. Neuroscience Research Communications, 1997, 20, 69-78.	0.2	18
70	Receptors for diadenosine polyphosphates P2D, P2YApnA, P4 and dinucleotide receptors: are there too many?. Trends in Pharmacological Sciences, 2000, 21, 135.	8.7	18
71	Elevated intraocular pressure increases melatonin levels in the aqueous humour. Acta Ophthalmologica, 2017, 95, e185-e189.	1.1	18
72	Adenine nucleotide effect on intraocular pressure: Involvement of the parasympathetic nervous system. Experimental Eye Research, 2009, 89, 63-70.	2.6	16

Jesús Pintor

#	Article	IF	CITATIONS
73	2-MeS-β,γ-CCl <sub>2</sub> -ATP is a Potent Agent for Reducing Intraocular Pressure. Journal of Medicinal Chemistry, 2010, 53, 3305-3319.	6.4	16
74	Involvement of carbonic anhydrases in the ocular hypotensive effect of melatonin analogue 5â€MCAâ€NAT. Journal of Pineal Research, 2012, 52, 265-270.	7.4	16
75	Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits. Journal of Optometry, 2018, 11, 69-74.	1.3	16
76	Silencing of P2Y2 receptor delays Ap4A-corneal re-epithelialization process. Molecular Vision, 2009, 15, 1169-78.	1.1	16
77	Presence of ε-adenosine tetraphosphate in chromaffin granules after transport of ε-ATP. FEBS Letters, 1996, 391, 195-198.	2.8	15
78	Melatonin potentiates tear secretion induced by diadenosine tetraphosphate in the rabbit. European Journal of Pharmacology, 2006, 552, 159-161.	3.5	15
79	Ocular disorders and the utility of animal models in the discovery of melatoninergic drugs with therapeutic potential. Expert Opinion on Drug Discovery, 2012, 7, 989-1001.	5.0	14
80	Presence and Release of ATP from the Retina in an Alzheimer's Disease Model. Journal of Alzheimer's Disease, 2014, 43, 177-181.	2.6	14
81	Differences in Dry Eye Questionnaire Symptoms in Two Different Modalities of Contact Lens Wear: Silicone-Hydrogel in Daily Wear Basis and Overnight Orthokeratology. BioMed Research International, 2016, 2016, 1-9.	1.9	14
82	The influence of rigid gas permeable lens wear on the concentrations of dinucleotides in tears and the effect on dry eye signs and symptoms in keratoconus. Contact Lens and Anterior Eye, 2016, 39, 375-379.	1.7	14
83	Effect of overnight orthokeratology on conjunctival goblet cells. Contact Lens and Anterior Eye, 2016, 39, 266-269.	1.7	14
84	A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist. Purinergic Signalling, 2018, 14, 271-284.	2.2	14
85	Hypotensive effect of profilin on rabbit intraocular pressure. European Journal of Pharmacology, 2007, 567, 145-148.	3.5	13
86	Purinergic Signalling in Immune System Regulation in Health and Disease. Mediators of Inflammation, 2015, 2015, 1-3.	3.0	12
87	The role of dinucleoside polyphosphates on the ocular surface and other eye structures. Progress in Retinal and Eye Research, 2016, 55, 182-205.	15.5	12
88	Expression of Melatonin and Dopamine D3 Receptor Heteromers in Eye Ciliary Body Epithelial Cells and Negative Correlation with Ocular Hypertension. Cells, 2020, 9, 152.	4.1	12
89	Phospholipase C/Protein Kinase C Pathway is Essential for Corneal Re-epithelialization Induced by Ap <sub>4</sub> A. Current Eye Research, 2011, 36, 1108-1115.	1.5	11
90	Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency. Experimental Eye Research, 2015, 134, 141-147.	2.6	11

#	Article	IF	CITATIONS
91	Optimization of a Rabbit Dry Eye Model Induced by Topical Instillation of Benzalkonium Chloride. Journal of Ophthalmology, 2020, 2020, 1-10.	1.3	11
92	Diadenosine polyphosphates release by human corneal epithelium. Experimental Eye Research, 2013, 113, 156-161.	2.6	10
93	Diadenosine polyphosphates in the tears of aniridia patients. Acta Ophthalmologica, 2015, 93, e337-42.	1.1	10
94	Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma. Purinergic Signalling, 2017, 13, 171-177.	2.2	10
95	Topical application of nucleotides increase lysozyme levels in tears. Clinical Ophthalmology, 2008, 2, 261-7.	1.8	10
96	P2Y receptors activated by diadenosine polyphosphates reestablish Ca2+ transients in achondroplasic chondrocytes. Bone, 2008, 42, 516-523.	2.9	9
97	Regulation of ocular adrenoceptor genes expression by 5-MCA-NAT. Pharmacogenetics and Genomics, 2011, 21, 587-589.	1.5	9
98	Effects of diadenosine tetraphosphate on FGF9-induced chloride flux changes in achondroplastic chondrocytes. Purinergic Signalling, 2011, 7, 243-249.	2.2	9
99	Melatonin synthesis in the human ciliary body triggered by TRPV4 activation: Involvement of AANAT phosphorylation. Experimental Eye Research, 2017, 162, 1-8.	2.6	9
100	Yellow Filter Effect on Melatonin Secretion in the Eye: Role in IOP Regulation. Current Eye Research, 2019, 44, 614-618.	1.5	9
101	Focus on Molecules: Diadenosine tetraphosphate. Experimental Eye Research, 2011, 92, 96-97.	2.6	8
102	Signs and Symptoms of Dry Eye in Keratoconus Patients Before and After Intrastromal Corneal Rings Surgery. Current Eye Research, 2017, 42, 513-519.	1.5	8
103	TRPV4 Stimulation Induced Melatonin Secretion by Increasing Arylalkymine N-acetyltransferase (AANAT) Protein Level. International Journal of Molecular Sciences, 2017, 18, 746.	4.1	8
104	Effect of Melatonin and Its Analogs on Tear Secretion. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 186-190.	2.5	8
105	Adreno–melatonin receptor complexes control ion homeostasis and intraocular pressure ―their disruption contributes to hypertensive glaucoma. British Journal of Pharmacology, 2020, 177, 2090-2105.	5.4	8
106	Effect of nutritional supplement based on melatonin on the intraocular pressure in normotensive subjects. International Ophthalmology, 2020, 40, 419-422.	1.4	8
107	Focus on Molecules: Purinergic P2Y2 receptor. Experimental Eye Research, 2012, 105, 83-84.	2.6	7
108	Effect of diinosine polyphosphates on intraocular pressure in normotensive rabbits. Experimental Eye Research, 2012, 101, 49-55.	2.6	7

#	Article	IF	CITATIONS
109	Therapeutic inhibitors for the treatment of dry eye syndrome. Expert Opinion on Pharmacotherapy, 2017, 18, 1855-1865.	1.8	6
110	Therapeutic potential of topical administration of siRNAs against HIF-1α for corneal neovascularization. Experimental Eye Research, 2022, 219, 109036.	2.6	6
111	Effect of PPADS on achondroplasic chondrocytes: Inhibition of FGF receptor type 3 over-activity. European Journal of Pharmacology, 2008, 584, 72-77.	3.5	5
112	Commentary. Purinergic Signalling, 2011, 7, 169-170.	2.2	5
113	Low expression of CD39 and CD73 genes in centenarians compared with octogenarians. Immunity and Ageing, 2017, 14, 11.	4.2	5
114	Effect of diadenosine polyphosphates in achondroplasic chondrocytes: Inhibitory effect of Ap4A on FGF9 induced MAPK cascade. Biochemical Pharmacology, 2007, 74, 448-456.	4.4	4
115	Understanding the Presence and Roles of Ap <sub>4</sub> A (Diadenosine Tetraphosphate) in the Eye. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 426-434.	1.4	4
116	Changes in P2Y Purinergic Receptor Expression in the Ciliary Body in a Murine Model of Glaucoma. Frontiers in Pharmacology, 2017, 8, 719.	3.5	4
117	Light-induced ATP release from the lens. Purinergic Signalling, 2018, 14, 499-504.	2.2	4
118	Diadenosine polyphosphates after laser <i>in situ</i> keratomileusis and photorefractive keratectomy refractive techniques. Acta Ophthalmologica, 2014, 92, e5-e11.	1.1	3
119	Contact lenses: new devices for nucleotide delivery in ocular pathologies. Purinergic Signalling, 2014, 10, 419-420.	2.2	3
120	Diadenosine tetraphosphate contributes to carbachol-induced tear secretion. Purinergic Signalling, 2015, 11, 87-93.	2.2	3
121	Increased Ap4A levels and ecto-nucleotidase activity in glaucomatous mice retina. Purinergic Signalling, 2018, 14, 259-270.	2.2	3
122	Pharmacology without drugs. Journal of Optometry, 2018, 11, 201-202.	1.3	3
123	Efficacy of Artificial Tears Based on an Extract of Artemia salina Containing Dinucleotides in a Rabbit Dry Eye Model. International Journal of Molecular Sciences, 2021, 22, 11999.	4.1	3
124	Adenine nucleotides and dinucleotides as new substances for the treatment of ocular hypertension and glaucoma. Current Opinion in Investigational Drugs, 2005, 6, 76-80.	2.3	3
125	Lactoferrin Levels in Tears are Increased by the Topical Application of Diadenosine Tetraphosphate. Current Eye Research, 2016, 41, 1150-1152.	1.5	2
126	Preclinical Development of Artificial Tears Based on an Extract of Artemia Salina Containing Dinucleotides in Rabbits. Current Eye Research, 2021, 46, 174-178.	1.5	2

#	Article	IF	CITATIONS
127	The impact of polyphenols on chondrocyte growth and survival: a preliminary report. Food and Nutrition Research, 2015, 59, 29311.	2.6	1
128	Changes in melatonin receptor expression in a murine model of glaucoma. Molecular Vision, 2020, 26, 530-539.	1.1	0